Molecular data
| Molecular formula | C194H312N54O59S2 |
|---|---|
| Molecular weight | 4409 Da |
| Sequence length | 37 residues |
| CAS / identifier | Cagri |
| Physical form | Lyophilized powder |
| Available sizes | 10mg |
How it works
-
AMY
Amylin Receptor Agonism
Binds amylin receptors (calcitonin receptor paired with RAMP1-3). Published characterisation describes satiety signalling, slowed gastric emptying and suppression of post-meal glucagon in study models.
- Satiety signalling measured
- Gastric emptying measured
- Post-meal glucagon measured
-
CTR
Calcitonin Receptor Co-Activation
Also activates the calcitonin receptor directly, a non-selective profile examined alongside its amylin receptor activity. Hindbrain regions such as the area postrema are the main sites studied.
- Calcitonin receptor agonism
- Hindbrain (area postrema) signalling
- Food intake measured
-
PK
Extended Half-Life Design
Structural changes reduce the fibrillation seen with native amylin, and a fatty-acid chain confers reversible albumin binding, extending the plasma half-life to roughly one week in research models.
- ~7-day half-life
- Albumin-binding modification
- Reduced fibrillation vs native amylin
What the research shows
-
Metabolic
Amylin Receptor Research
Amylin signalling is a growing focus of metabolic research, and Cagri is a long-acting amylin analogue used as a reference compound in that work.
-
Combination
Amylin + GLP-1 Research
Because amylin and GLP-1 act through different receptors, Cagri is studied alongside GLP-1 receptor agonists such as GLP-1 S in combination research.
-
Endocrine
Glycemic Pathway Research
Amylin's effects on post-meal glucagon and gastric emptying make Cagri a subject of glycemic pathway research.
-
Neuroscience
Hindbrain Satiety Circuitry
Amylin receptors in the area postrema and connected hindbrain circuits modulate satiety, a focus of ongoing neuroscience research.
Specification
| Compound Class | Long-acting amylin analogue |
|---|---|
| Research Name | Cagri |
| Target | Amylin receptors (AMY1-3) and calcitonin receptor (CTR) |
| Form | Lyophilized powder |
| Molecular Weight | 4,409 g/mol |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Half-Life | ~7 days |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
How it's tested
Every lot of Cagri released to the catalog carries a third-party certificate of analysis. 1 documented lot is on file for this compound, with reported HPLC purity from 99.70% to 99.70% (mean 99.70%), issued by Freedom Diagnostics. 1 of 1 certificates record identity as confirmed.
- Documented lots
- 1
- Reported purity
- 99.70% to 99.70%
- Mean purity
- 99.70%
- Issuing labs
- Freedom Diagnostics
- 2026-10-03 Lot R56A0BFreedom Diagnostics 99.70% View certificate
Frequently asked questions
What is Cagri?
Cagri is a long-acting analogue of the pancreatic hormone amylin. It activates amylin receptors and the calcitonin receptor; published characterisation describes satiety signalling, slowed gastric emptying and suppression of post-meal glucagon.
How does it differ from GLP-1 S, GLP-2 TZ and GLP-3 RT?
The GLP compounds act on incretin receptors (GLP-1, GIP, glucagon). Cagri acts on a different system entirely: amylin and calcitonin receptors. That is why it is studied alongside GLP-1 receptor agonists in combination research.
What is the molecular weight and purity?
Cagri has a molecular weight of 4,409 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.
How should it be stored?
Store lyophilized vials at -20°C for long-term stability, protected from light and moisture.
Is this product for human use?
No. Cagri is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.
Cross-references
Other entries in this volume that bear on Cagri, with the reason each one is listed.
- GLP-3 / Cagri blend carrying this compound Two-peptide blend · 10 mg / 2 mg lyophilized
- GLP-2 / Cagri blend carrying this compound Incretin + amylin blend · 10 mg lyophilized
- GLP-3 / Tesa / Cagri blend carrying this compound Three-compound blend · 17.5 mg lyophilized
- Cagri / GLP-1 blend carrying this compound Amylin + incretin blend · 10 mg lyophilized
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.